Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study

Lamis Kaddam, Imad FdleAlmula, Omer Ali Eisawi, Haydar Awad Abdelrazig, Mustafa Elnimeiri, Florian Lang, Amal M Saeed, Lamis Kaddam, Imad FdleAlmula, Omer Ali Eisawi, Haydar Awad Abdelrazig, Mustafa Elnimeiri, Florian Lang, Amal M Saeed

Abstract

Background: High levels of fetal haemoglobin (HbF) decrease sickle cell anaemia (SCA) severity and leads to improved survival. According to in vivo and in vitro studies, butyrate increases HbF production. Its utilization in clinical practice is hampered, however, by its short half-life. Serum butyrate concentrations could be enhanced by colonic bacterial fermentation of Gum Arabic (GA), edible, dried, gummy exudates from Acacia Senegal tree. We hypothesized that regular intake of GA increases serum butyrate levels, thus inducing HbF production and ameliorating symptoms of sickle cell anemia.

Methods: Fourty seven patients (5-42 years) carrying hemoglobin SS were recruited from April 2014 to January 2015. Patients received 30 g/day GA for 12 weeks. HbF, blood count and erythropoietin level were measured. The main outcome of interest was the level of HbF after 12 weeks. The secondary outcomes were improvement in clinical and laboratory results. The study was ethically approved by Alneelain University IRB.

Results: The study revealed significant increase in HbF level P.V0.000 [95 % CI, 0.43-1.02], MCV P.V:000 [95 % CI, 2.312-6.058] and Hematocrit level P.V:0.026 [95 % CI, 0.124-1.902]. No significant difference was encountered in platelets count P.V: 0.346 [95 % CI,-25.76-71.94], and WBCs count P.V:0.194 [95 % CI,-8.035-1.68]. Thirty seven percent of patients experienced minor side effects which resolved within a week.

Conclusion: These findings reveal a novel effect of GA, which may be used to foster fetal hemoglobin production.

Trial registration: ClinicalTrials.gov Identifier: NCT02467257. Registered 3rd June 2015.

Figures

Fig. 1
Fig. 1
Hb F value from baseline to week 12, by subject. Each symbol represents one patient. Patients 41–47 are on HU dose
Fig. 2
Fig. 2
Effect of GA intake on MCV (P = 0.000). * indicates significant difference from baseline
Fig. 3
Fig. 3
Effect of GA intake on MCHC (P = 0.000). * indicates significant difference from baseline

References

    1. Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program 2006;58–62.
    1. Lang E, Lang F. Triggers, inhibitors, mechanisms, and significance of eryptosis: The suicidal erythrocyte death. Biomed Res Int. 2015;2015:513518. doi: 10.1155/2015/513518.
    1. Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol. 2009;82(4):315–21. doi: 10.1111/j.1600-0609.2009.01210.x.
    1. Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FI, Bassi SC, Santis GC, et al. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: A single-center experience in Brazil. Sao Paulo Med J. 2013;131(4):238–43. doi: 10.1590/1516-3180.2013.1314467.
    1. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27. doi: 10.1182/blood-2011-03-325258.
    1. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10–4. doi: 10.1182/blood.V99.1.10.
    1. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009;62–9. doi: 10.1182/asheducation-2009.1.62.
    1. Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, et al. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013;88(11):E255–E260. doi: 10.1002/ajh.23533.
    1. Diallo DA, Guindo A. Sickle cell disease in sub-Saharan Africa: Stakes and strategies for control of the disease. Curr Opin Hematol. 2014;21(3):210–4. doi: 10.1097/MOH.0000000000000038.
    1. Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790–7.
    1. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med. 1992;327(8):569–70.
    1. Fathallah H, Weinberg RS, Galperin Y, Sutton M, Atweh GF. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood. 2007;110(9):3391–7. doi: 10.1182/blood-2007-02-076091.
    1. Hines P, Dover GJ, Resar LM. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer. 2008;50(2):357–9. doi: 10.1002/pbc.21104.
    1. Resar LM, Segal JB, Fitzpatric LK, Friedmann A, Brusilow SW, Dover GJ. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 2002;24(9):737–41. doi: 10.1097/00043426-200212000-00011.
    1. Ali BH, Ziada A, Blunden G. Biological effects of gum arabic: A review of some recent research. Food Chem Toxicol. 2009;47(1):1–8. doi: 10.1016/j.fct.2008.07.001.
    1. Babiker R, Merghani TH, Elmusharaf K, Badi RM, Lang F, Saeed AM. Effects of Gum Arabic ingestion on body mass index and body fat percentage in healthy adult females: two-arm randomized, placebo controlled, double-blind trial. Nutr J. 2012;11:111. doi: 10.1186/1475-2891-11-111.
    1. Ballal A, Bobbala D, Qadri SM, Foller M, Kempe D, Nasir O, et al. Anti-malarial effect of gum arabic. Malar J. 2011;10:139. doi: 10.1186/1475-2875-10-139.
    1. Tulung B, Remesy C, Demigne C. Specific effect of guar gum or gum arabic on adaptation of cecal digestion to high fiber diets in the rat. J Nutr. 1987;117(9):1556–61.
    1. Matsumoto N, Riley S, Fraser D, Al-Assaf S, Ishimura E, Wolever T, et al. Butyrate modulates TGF-beta1 generation and function: Potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? Kidney Int. 2006;69(2):257–65. doi: 10.1038/sj.ki.5000028.
    1. Nasir O. Renal and extrarenal effects of gum arabic (Acacia senegal)--what can be learned from animal experiments? Kidney Blood Press Res. 2013;37(4–5):269–79. doi: 10.1159/000350152.
    1. Ali BH, Al-Husseni I, Beegam S, Al-Shukaili A, Nemmar A, Schierling S, et al. Effect of gum arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats. PLoS One. 2013;8(2):e55242. doi: 10.1371/journal.pone.0055242.
    1. Nasir O, Umbach AT, Rexhepaj R, Ackermann TF, Bhandaru M, Ebrahim A, et al. Effects of gum arabic (Acacia senegal) on renal function in diabetic mice. Kidney Blood Press Res. 2012;35(5):365–72. doi: 10.1159/000336359.
    1. Ali BH, Al ZaGÇÖabi M, Ramkumar A, Yasin J, Nemmar A. Anemia in adenine-induced chronic renal failure and the influence of treatment with gum acacia thereon. Physiol Res. 2014;63(3):351–8.
    1. Ali BH, Beegam S, Al Lawati I, Waly MI, Nemmar A. Comparative efficacy of three brands of gum arabic on adenineGÇôinduced chronic renal failure in rats. Physiol Res. 2013;62(1):47–56.
    1. de FL, Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica. 2004;89(3):348–56.
    1. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood. 2008;112(10):3927–38. doi: 10.1182/blood-2008-04-078188.
    1. Orringer EP, Blythe DS, Johnson AE, Phillips G, Jr, Dover GJ, Parker JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood. 1991;78(1):212–6.
    1. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–32. doi: 10.1182/blood.V97.11.3628.
    1. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–45. doi: 10.1182/blood-2003-07-2475.
    1. Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol. 1997;98(4):838–44. doi: 10.1046/j.1365-2141.1997.3173132.x.
    1. Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatr Hydroxyurea Group Blood. 1999;94(5):1550–4.
    1. Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol. 2003;72(2):121–6. doi: 10.1002/ajh.10264.
    1. Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in beta-thalassaemia intermedia and HbE/beta-thalassaemia. Br J Haematol. 2013;161(4):587–93. doi: 10.1111/bjh.12304.
    1. Bartolucci P, Brugnara C, Teixeira-Pinto A, Pissard S, Moradkhani K, Jouault H, et al. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012;120(15):3136–41. doi: 10.1182/blood-2012-04-424184.
    1. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46(1):105–10. doi: 10.1111/j.1537-2995.2006.00679.x.
    1. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood. 1993;81(1):9–14.
    1. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993;328(2):73–80. doi: 10.1056/NEJM199301143280201.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere